公开(公告)号：EP4338738A3

公开(公告)日：2024-06-19

申请号：EP23211155.9

申请日：2016-03-02

申请人： Pharmacyclics LLC

发明人： ATLURI,, Harisha ,  CHONG,, Ching, Wah ,  KUEHL,, Robert ,  TAN,, Heow

IPC分类号： A61K31/436 ,  A61K31/519

CPC分类号： A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2095 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00

摘要： Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：EP4338738A2

公开(公告)日：2024-03-20

申请号：EP23211155.9

申请日：2016-03-02

申请人： Pharmacyclics LLC

发明人： ATLURI,, Harisha ,  CHONG,, Ching, Wah ,  KUEHL,, Robert ,  TAN,, Heow

IPC分类号： A61K31/519

摘要： Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.